Experienced in Hepatic Venoocclusive Disease with Immunodeficiency

Yongchang M. Zhang

No.87 Xiangya Road, 
Changsha, CN 
Experienced in Hepatic Venoocclusive Disease with Immunodeficiency
No.87 Xiangya Road, 
Changsha, CN 
OverviewLocationsClinical Research

Overview

Yongchang Zhang practices in Changsha, China. Zhang is rated as an Experienced expert by MediFind in the treatment of Hepatic Venoocclusive Disease with Immunodeficiency. Their top areas of expertise are Lung Cancer, EGFR Positive Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Lung Adenocarcinoma, and Tissue Biopsy.

Their clinical research consists of co-authoring 151 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 2 articles in the study of Hepatic Venoocclusive Disease with Immunodeficiency.

Locations

No.87 Xiangya Road, Changsha, 410008, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Phase II Study on Toripalimab Combined With Double Platinum Based Chemotherapy for as a Neoadjuvant Therapy for Initially Unresectable Non-driver Gene Mutation Non-small Cell Lung Cancer
A Phase II Study on Toripalimab Combined With Double Platinum Based Chemotherapy for as a Neoadjuvant Therapy for Initially Unresectable Non-driver Gene Mutation Non-small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: August 09, 2024
Intervention Type: Drug
Study Drug: Treprilumab+Platinum based chemotherapy
Study Phase: Phase 2
Multiple-center, Single-arm, Phase II Study on Sintilimab Combined With Docetaxel in Non-driver Gene Mutation Advanced NSCLC Patients Who Had Failed With Double Platinum-based Chemotherapy
Multiple-center, Single-arm, Phase II Study on Sintilimab Combined With Docetaxel in Non-driver Gene Mutation Advanced NSCLC Patients Who Had Failed With Double Platinum-based Chemotherapy
Enrollment Status: Completed
Publish Date: March 02, 2022
Intervention Type: Drug
Study Drug: Sintilimab+Docetaxel Monotherapy
Study Phase: Phase 2
the Effectiveness and Safety Study on Apatinib Combined With Vinorelbine Used for Driver Gene Mutation Negative Third-line and Third-line Post Progression Advanced Non-small Cell Lung Cancer
the Effectiveness and Safety Study on Apatinib Combined With Vinorelbine Used for Driver Gene Mutation Negative Third-line and Third-line Post Progression Advanced Non-small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: February 17, 2020
Intervention Type: Drug
Study Phase: Phase 2
View 2 Less Clinical Trials

151 Total Publications

Prognostic implications of uncommon EGFR exon 19 deletion-insertion mutations in non-small cell lung cancer treated with third-generation EGFR-TKIs.
Prognostic implications of uncommon EGFR exon 19 deletion-insertion mutations in non-small cell lung cancer treated with third-generation EGFR-TKIs.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: June 30, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Zhang's expertise for a condition
ConditionClose
View All 16 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile